PMID- 30170601
OWN - NLM
STAT- MEDLINE
DCOM- 20190128
LR  - 20230928
IS  - 1475-2840 (Electronic)
IS  - 1475-2840 (Linking)
VI  - 17
IP  - 1
DP  - 2018 Aug 31
TI  - Endothelial dysfunction and platelet hyperactivity in type 2 diabetes mellitus: 
      molecular insights and therapeutic strategies.
PG  - 121
LID - 10.1186/s12933-018-0763-3 [doi]
LID - 121
AB  - The incidence and prevalence of diabetes mellitus is rapidly increasing worldwide 
      at an alarming rate. Type 2 diabetes mellitus (T2DM) is the most prevalent form 
      of diabetes, accounting for approximately 90-95% of the total diabetes cases 
      worldwide. Besides affecting the ability of body to use glucose, it is associated 
      with micro-vascular and macro-vascular complications. Augmented atherosclerosis 
      is documented to be the key factor leading to vascular complications in T2DM 
      patients. The metabolic milieu of T2DM, including insulin resistance, 
      hyperglycemia and release of excess free fatty acids, along with other metabolic 
      abnormalities affects vascular wall by a series of events including endothelial 
      dysfunction, platelet hyperactivity, oxidative stress and low-grade inflammation. 
      Activation of these events further enhances vasoconstriction and promotes 
      thrombus formation, ultimately resulting in the development of atherosclerosis. 
      All these evidences are supported by the clinical trials reporting the importance 
      of endothelial dysfunction and platelet hyperactivity in the pathogenesis of 
      atherosclerotic vascular complications. In this review, an attempt has been made 
      to comprehensively compile updated information available in context of 
      endothelial and platelet dysfunction in T2DM.
FAU - Kaur, Raminderjit
AU  - Kaur R
AD  - Department of Molecular Biology & Biochemistry, Guru Nanak Dev University, 
      Amritsar, Punjab, India.
FAU - Kaur, Manpreet
AU  - Kaur M
AD  - Department of Human Genetics, Guru Nanak Dev University, Amritsar, Punjab, India.
FAU - Singh, Jatinder
AU  - Singh J
AD  - Department of Molecular Biology & Biochemistry, Guru Nanak Dev University, 
      Amritsar, Punjab, India. jatinterarora2009@gmail.com.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20180831
PL  - England
TA  - Cardiovasc Diabetol
JT  - Cardiovascular diabetology
JID - 101147637
RN  - 0 (Biomarkers)
RN  - 0 (Blood Glucose)
RN  - 0 (Fibrinolytic Agents)
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Inflammation Mediators)
RN  - 0 (Platelet Aggregation Inhibitors)
SB  - IM
MH  - Animals
MH  - Atherosclerosis/*blood/drug therapy/epidemiology/physiopathology
MH  - Biomarkers/blood
MH  - Blood Glucose/metabolism
MH  - Blood Platelets/drug effects/*metabolism
MH  - Diabetes Mellitus, Type 2/*blood/drug therapy/epidemiology/physiopathology
MH  - Diabetic Angiopathies/*blood/drug therapy/epidemiology/physiopathology
MH  - Endothelium, Vascular/drug effects/*metabolism/physiopathology
MH  - Fibrinolytic Agents/therapeutic use
MH  - Humans
MH  - Hypoglycemic Agents/therapeutic use
MH  - Inflammation Mediators/blood
MH  - Oxidative Stress
MH  - *Platelet Activation/drug effects
MH  - Platelet Aggregation Inhibitors/therapeutic use
MH  - Thrombosis/*blood/drug therapy/epidemiology/physiopathology
MH  - *Vasoconstriction/drug effects
PMC - PMC6117983
OTO - NOTNLM
OT  - Hyperglycemia
OT  - Inflammation
OT  - Insulin resistance
OT  - Oxidative stress
OT  - Vascular complications
EDAT- 2018/09/02 06:00
MHDA- 2019/01/29 06:00
PMCR- 2018/08/31
CRDT- 2018/09/02 06:00
PHST- 2018/07/19 00:00 [received]
PHST- 2018/08/20 00:00 [accepted]
PHST- 2018/09/02 06:00 [entrez]
PHST- 2018/09/02 06:00 [pubmed]
PHST- 2019/01/29 06:00 [medline]
PHST- 2018/08/31 00:00 [pmc-release]
AID - 10.1186/s12933-018-0763-3 [pii]
AID - 763 [pii]
AID - 10.1186/s12933-018-0763-3 [doi]
PST - epublish
SO  - Cardiovasc Diabetol. 2018 Aug 31;17(1):121. doi: 10.1186/s12933-018-0763-3.